Related references
Note: Only part of the references are listed.Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia
Heinz Ludwig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius et al.
LANCET (2009)
Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer
Alok A. Khorana et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
Gillian Thomas et al.
GYNECOLOGIC ONCOLOGY (2008)
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
Robert E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide
Robert Pirker et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
James R. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update
C. Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2007)
Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp (R)) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) - the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial
J. Overgaard et al.
EJC SUPPLEMENTS (2007)
Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
Julia Bohlius et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia
JL Canon et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature
Susan D. Ross et al.
CLINICAL THERAPEUTICS (2006)
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The rationale for pathogen-inactivation treatment of blood components
JAJ Barbara
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
A note on competing risks in survival data analysis
JM Satagopan et al.
BRITISH JOURNAL OF CANCER (2004)
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:: randomised, double-blind, placebo-controlled trial
M Henke et al.
LANCET (2003)
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
M Hedenus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes
D Cella et al.
ANNALS OF ONCOLOGY (2003)
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
TJ Littlewood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
JL Gabrilove et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
